化合物 TIC10|T7001|TargetMol

价格	￥218	￥498	￥721
包装	1mg	5mg	10mg

最小起订量	1mg
发货地	上海
更新日期	2025-11-17

QQ交谈微信洽谈

产品详情

中文名称:化合物 TIC10	英文名称:TIC10
CAS:1616632-77-9	品牌: TargetMol
产地: 美国	保存条件: keep away from moisture,store at low temperature,store under nitrogen \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
纯度规格: 99.98%	产品类别: 抑制剂
货号: T7001

Product Introduction

Bioactivity

名称	TIC10
描述	TIC10 (ONC-201) inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
细胞实验	TIC10 is prepared in DMSO and stored, and then diluted with appropriate medium before use[1]. Floating and adherent cells are analyzed on a Coulter-Beckman Elite Epics cytometer. For surface TRAIL experiments, adherent cells are harvested by brief trypsinization, fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min, incubated with an anti-TRAIL antibody at 1:250 overnight, washed and incubated with anti-rabbit Alexa Fluor 488 for 30 min, and analyzed. Cells are gated on forward and side scatter to eliminate debris and dead cells from the analysis. Surface TRAIL data are expressed as median fluorescence intensity relative to that of control samples unless indicated otherwise. Surface DR5 is analyzed similarly with an antibody from Imgenex. For sub-G1content and cell cycle profile analysis, all cells are pelleted and ethanol-fixed, followed by staining with propidium iodide in the presence of RNase. Cell viability assays are carried out in 96-well black-walled clear-bottom plates with CellTiter-Glo[1].
体外活性	TIC10 causes a dose-dependent increase in TRAIL mRNA and induces TRAIL protein localization on the cell surface of several cancer cell lines in a p53-independent manner. TIC10 has broad-spectrum activity against multiple malignancies in vitro and induces an increase in sub-G1 DNA content suggestive of cell death in TRAIL-sensitive HCT116 p53?/? cells, but does not alter the cell cycle profiles of normal fibroblasts at equivalent doses. TIC10 decreases the clonogenic survival of cancer cell lines and spares normal fibroblasts. TIC10 increases the percentage of sub-G1 DNA in cancer cells in a p53-independent and Bax-dependent manner, as previously reported for TRAIL-mediated apoptosis. TIC10-induced TRAIL up-regulation is Foxo3a-dependent, which also up-regulates TRAIL death receptor DR5 among other targets, potentially allowing for sensitization of some TRAIL-resistant tumor cells. TIC10 inactivates kinases Akt and extracellular signal–regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription. TIC10 is an efficacious antitumor therapeutic agent that acts on tumor cells and their microenvironment to enhance the concentrations of the endogenous tumor suppressor TRAIL. [1]
体内活性	TIC10 and TRAIL treatment causes tumor regression in the HCT116 p53?/? xenograft to a comparable extent when both are administered as multiple doses. TIC10 also induces regression of MDA-MB-231 human triple-negative breast cancer xenografts, whereas TRAIL-treated tumors progressed. In DLD-1 colon cancer xenografts, TIC10 induces tumor stasis at 1 week after treatment, whereas TRAIL-treated tumors progresses after a single dose. A single dose of TIC10 also induces a sustained regression of the SW480 xenograft and is equally effective when delivered by intraperitoneal or oral route, suggesting favorable oral bioavailability for TIC10. TIC10 causes tumor-specific cell death by TRAIL-mediated direct and bystander effects. TIC10 is an effective antitumor agent against orthotopic human glioblastoma multiforme tumors. [1]
存储条件	keep away from moisture,store at low temperature,store under nitrogen \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
溶解度	Ethanol : 71 mg/mL (183.7 mM), Sonication is recommended. DMSO : 65 mg/mL (168.18 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble)
关键字	Tumor Necrosis Factor Receptor \| TNFR \| TNF Receptor \| TIC-10 \| TIC10 \| TIC 10 \| ONC201 \| ONC 201 \| Inhibitor \| inhibit \| Apoptosis \| Akt
相关产品	Urea \| Kaolin \| Dimethyl phthalate \| Aceglutamide \| Alginic acid \| Cysteamine hydrochloride \| Metronidazole \| Dextran sulfate sodium salt (MW 5000) \| Citric Acid Triammonium \| Stavudine \| Sodium 4-phenylbutyrate \| Ethyl linoleate
相关库	经典已知活性库 \| 抗癌活性化合物库 \| 抗癌化合物库 \| 已知活性化合物库 \| 细胞因子抑制剂库 \| 激酶抑制剂库 \| 抗衰老化合物库 \| 膜蛋白靶向化合物库 \| 免疫/炎症分子化合物库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

关键字： ONC-201|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	2013-04-18 （13年）	注册资本	566.265100万人民币
员工人数	100-500人	年营业额	￥ 1亿以上
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务	经营模式	贸易,工厂,试剂,定制,服务

TargetMol中国（陶术生物）

VIP 4年

公司成立：13年
注册资本：566.265100万人民币
企业类型：有限责任公司(自然人投资或控股)
主营产品：小分子抑制剂、药物筛选化合物库、药物筛选等
公司地址：静安区江场三路238号8楼

进入店铺

询盘

店内推荐

化合物 CV-6209|T27102|TargetMol

￥1320

TNF-α-IN-2|T36097|TargetMol

￥5910

异丙碘胺|T5051|TargetMol

￥119

化合物 TIC10|T7001|TargetMol相关厂家报价

产品名称	价格		公司名称	报价日期
onc01	询价	VIP4年	深圳药缘研发中心有限公司	2026-01-05
甲基苄基	询价	VIP6年	河南威梯希化工科技有限公司	2025-12-25
ONCTIC10 ( ONC201 ) , ≧99.0% \| TRAIL inducer	￥500	VIP16年	武汉永璨生物科技有限公司	2025-11-19
CAS:1616632-77-9 ONC201	询价		裕通医药科技（上海）有限公司	2025-10-16
aladdin 阿拉丁 T413890 TIC10 (ONC201) 1616632-77-9 98%	￥556.90	VIP2年	上海阿拉丁生化科技股份有限公司	2025-05-16
甲基苄基	询价		广东山药生物科技有限公司	2021-04-09
TRAIL 诱导剂ONC201，TIC10	询价	VIP4年	深圳药缘研发中心有限公司	2026-01-05

内容声明:
以上所展示的信息由商家自行提供，内容的真实性、准确性和合法性由发布商家负责。商家发布价格指该商品的参考价格，并非原价，该价格可能随着市场变化，或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格，请咨询商家，以实际成交价格为准。请意识到互联网交易中的风险是客观存在的